Electroporation Gene Therapy

Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition

Volumn , Issue , 2013, Pages 93-106

  Shirley, Shawna A ^a   Heller, Richard ^a   Heller, Loree C ^a  

^a OLD DOMINION UNIVERSITY   (United States)

Author keywords

Cancer; Electroporation; Gene therapy; Nucleic acids; Vaccine

Indexed keywords

EID: 84904085843     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394295-1.00007-X     Document Type: Chapter

References (127)

1. Neumann E., Schaefer-Ridder M., Wang Y., Hofschneider P.H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982, 1(7):841-845.
2. Neumann E., Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol 1972, 10(3):279-290.
3. Belehradek M., Domenge C., Luboinski B., Orlowski S., Belehradek J., Mir L.M. Electrochemotherapy, a new antitumor treatment: first clinical phase I-II trial. Cancer 1993, 72(12):3694-3700.
4. Li S. Electroporation protocols: experimental and clinical gene medicine 2008, Humana, Totowa, NJ.
5. Neumann E., Kakorin S., Toensing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg 1999, 48(1):3-16.
6. Weaver J.C. Molecular basis for cell membrane electroporation. Ann N Y Acad Sci 1994, 720:141-152.
7. Davalos R.V., Mir I.L., Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005, 33(2):223-231.
8. Joshi R.P., Schoenbach K.H. Mechanism for membrane electroporation irreversibility under high-intensity, ultrashort electrical pulse conditions. Phys Rev E Stat Nonlin Soft Matter Phys 2002, 66(5 Pt 1):052901.
9. Onik G., Mikus P., Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007, 6(4):295-300.
10. Rubinsky B. Irreversible electroporation in medicine. Technol Cancer Res Treat 2007, 6(4):255-260.
11. Gabriel B., Teissie J. Direct observation in the millisecond time range of fluorescent molecule asymmetrical interaction with the electropermeabilized cell membrane. Biophys J 1997, 73(5):2630-2637.
12. Ibey B.L., Mixon D.G., Payne J.A., Bowman A., Sickendick K., Wilmink G.J., et al. Plasma membrane permeabilization by trains of ultrashort electric pulses. Bioelectrochemistry 2010, 79(1):114-121.
13. Pakhomov A.G., Kolb J.F., White J.A., Joshi R.P., Xiao S., Schoenbach K.H. Long-lasting plasma membrane permeabilization in mammalian cells by nanosecond pulsed electric field (nsPEF). Bioelectromagnetics 2007, 28(8):655-663.
14. Pakhomov A.G., Shevin R., White J.A., Kolb J.F., Pakhomova O.N., Joshi R.P., et al. Membrane permeabilization and cell damage by ultrashort electric field shocks. Arch Biochem Biophys 2007, 465(1):109-118.
15. Vernier P.T., Sun Y., Gundersen M.A. Nanoelectropulse-driven membrane perturbation and small molecule permeabilization. BMC Cell Biol 2006, 7:37.
16. Silve A., Leray I., Mir L.M. Demonstration of cell membrane permeabilization to medium-sized molecules caused by a single 10ns electric pulse. Bioelectrochemistry 2012, 87:260-264.
17. Schoenbach K.H., Beebe S.J., Buescher E.S. Intracellular effect of ultrashort electrical pulses. Bioelectromagnetics 2001, 22(6):440-448.
18. Beebe S.J., Fox P.M., Rec L.J., Willis E.L., Schoenbach K.H. Nanosecond, high-intensity pulsed electric fields induce apoptosis in human cells. FASEB J 2003, 17(11):1493-1495.
19. Deng J., Schoenbach K.H., Buescher E.S., Hair P.S., Fox P.M., Beebe S.J. The effects of intense submicrosecond electrical pulses on cells. Biophys J 2003, 84(4):2709-2714.
20. Beebe S.J., Chen X., Liu J.A., Schoenbach K.H. Nanosecond pulsed electric field ablation of hepatocellular carcinoma. Conf Proc IEEE Eng Med Biol Soc 2011, 2011:6861-6865.
21. Chen X., Zhuang J., Kolb J.F., Schoenbach K.H., Beebe S.J. Long term survival of mice with hepatocellular carcinoma after pulse power ablation with nanosecond pulsed electric fields. Technol Cancer Res Treat 2012, 11(1):83-93.
22. Nuccitelli R., Pliquett U., Chen X., Ford W., James Swanson R., Beebe S.J., et al. Nanosecond pulsed electric fields cause melanomas to self-destruct. Biochem Biophys Res Commun 2006, 343(2):351-360.
23. Nuccitelli R., Tran K., Sheikh S., Athos B., Kreis M., Nuccitelli P. Optimized nanosecond pulsed electric field therapy can cause murine malignant melanomas to self-destruct with a single treatment. Int J Cancer 2010, 127(7):1727-1736.
24. Neumann E., Toensing K., Kakorin S., Budde P., Frey J. Mechanism of electroporative dye uptake by mouse B cells. Biophysical Journal 1998, 74(1):98-108.
25. Sukharev S.I., Klenchin V.A., Serov S.M., Chernomordik L.V., Chizmadzhev Y.u.A. Electroporation and electrophoretic DNA transfer into cells: the effect of DNA interaction with electropores. Biophys J 1992, 63(5):1320-1327.
26. Rosazza C., Phez E., Escoffre J.M., Cezanne L., Zumbusch A., Rols M.P. Cholesterol implications in plasmid DNA electrotransfer: evidence for the involvement of endocytotic pathways. Int J Pharm 2012, 423(1):134-143.
27. Spassova M., Tsoneva I., Petrov A.G., Petkova J.I., Neumann E. Dip patch clamp currents suggest electrodiffusive transport of the polyelectrolyte DNA through lipid bilayers. Biophys Chem 1994, 52(3):267-274.
28. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(10):5257-5269.
29. Lavigne M.D., Gorecki D.C. Emerging vectors and targeting methods for nonviral gene therapy. Expert Opin Emerg Drugs 2006, 11(3):541-557.
30. Li S.D., Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 2006, 13(18):1313-1319.
31. Gao X., Kim K.S., Liu D. Nonviral gene delivery: what we know and what is next. Aaps J 2007, 9(1):E92-E104.
32. Mir L.M., Glass L.F., Sersa G., Teissie J., Domenge C., Miklavcic D., et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998, 77(12):2336-2342.
33. Gothelf A., Mir L.M., Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003, 29(5):371-387.
34. Okino M., Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987, 78(12):1319-1321.
35. Titomirov A.V., Sukharev S., Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1991, 1088(1):131-134.
36. Heller R., Jaroszeski M., Atkin A., Moradpour D., Gilbert R., Wands J., et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996, 389(3):225-228.
37. Nishi T., Yoshizato K., Yamashiro S., Takeshima H., Sato K., Hamada K., et al. High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Cancer Res 1996, 56(5):1050-1055.
38. Heller L.C., Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006, 17(9):890-897.
39. Marshall W.G., Boone B.A., Burgos J.D., Gografe S.I., Baldwin M.K., Danielson M.L., et al. Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression. Gene Ther 2010, 17(3):419-423.
40. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003, 177(4):437-447.
41. Mir L.M. Application of electroporation gene therapy: past, current, and future. Methods Mol Biol 2008, 423:3-17.
42. Andre F., Mir L.M. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 2004, 11(Suppl. 1):S33-S42.
43. Heller L.C., Ugen K., Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2005, 2(2):255-268.
44. Gehl J., Mir L.M. Determination of optimal parameters for in vivo gene transfer by electroporation, using a rapid in vivo test for cell permeabilization. Biochem Biophys Res Commun 1999, 261(2):377-380.
45. Somiari S., Glasspool-Malone J., Drabick J.J., Gilbert R.A., Heller R., Jaroszeski M.J., et al. Theory and in vivo application of electroporative gene delivery. Mol Ther 2000, 2(3):178-187.
46. Heller R., Cruz Y., Heller L.C., Gilbert R.A., Jaroszeski M.J. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Hum Gene Ther 2010, 21(3):357-362.
47. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999, 96(8):4262-4267.
48. Lucas M.L., Heller R. Immunomodulation by electrically enhanced delivery of plasmid DNA encoding IL-12 to murine skeletal muscle. Mol Ther 2001, 3(1):47-53.
49. Heller L., Jaroszeski M.J., Coppola D., Pottinger C., Gilbert R., Heller R. Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo. Gene Ther 2000, 7(10):826-829.
50. Heller L.C., Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010, 10(4):312-317.
51. Marrero B., Heller R. The use of an in vitro 3D melanoma model to predict in vivo plasmid transfection using electroporation. Biomaterials 2012, 33:3036-3046.
52. Mesojednik S., Pavlin D., Sersa G., Coer A., Kranjc S., Grosel A., et al. The effect of the histological properties of tumors on transfection efficiency of electrically assisted gene delivery to solid tumors in mice. Gene Ther 2007, 14(17):1261-1269.
53. Cemazar M., Golzio M., Sersa G., Escoffre J.M., Coer A., Vidic S., et al. Hyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumors. Hum Gene Ther 2012, 23(1):128-137.
54. Henshaw J., Mossop B., Yuan F. Enhancement of electric field-mediated gene delivery through pretreatment of tumors with a hyperosmotic mannitol solution. Cancer Gene Ther 2011, 18(1):26-33.
55. Dharmapuri S., Aurisicchio L., Neuner P., Verdirame M., Ciliberto G., La Monica N. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther 2009, 16(5):462-472.
56. Ohlschlager P., Spies E., Alvarez G., Quetting M., Groettrup M. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 2011, 128(2):473-481.
57. Yang L.J., Yu W.D., Du J.B., Chao S., Chen M.X., Zhao H.H., et al. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice. Chin Med J (Engl) 2009, 122(3):331-337.
58. Fu J., Zhao B., Dong Z., Sun Y., Luan H., Shen X., et al. Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models. Vaccine 2012, 30:2187-2196.
59. Haller B.K., Brave A., Wallgard E., Roswall P., Sunkari V.G., Mattson U., et al. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma. Oncogene 2010, 29(30):4276-4286.
60. Duces A., Karaky R., Martel-Renoir D., Mir L., Hamma-Kourbali Y., Bieche I., et al. 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development. Mol Cancer Ther 2008, 7(9):2817-2827.
61. Roos A.K., Moreno S., Leder C., Pavlenko M., King A., Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006, 13(2):320-327.
62. Ahmad S., Casey G., Sweeney P., Tangney M., O'Sullivan G.C. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther 2010, 8(1):1.
63. Goepfert C., Gazdhar A., Frey F.J., Frey B.M. Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice. Prostate 2011, 71(8):872-880.
64. Cho H.I., Celis E. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma. Cancer Immunol Immunother 2012, 61:345-351.
65. Shibata M.A., Ambati J., Shibata E., Albuquerque R.J., Morimoto J., Ito Y., et al. The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model. BMC Med 2010, 8:69.
66. Verrax J., Defresne F., Lair F., Vandermeulen G., Rath G., Dessy C., et al. Delivery of soluble VEGF receptor 1 (sFlt1) by gene electrotransfer as a new antiangiogenic cancer therapy. Mol Pharm 2011, 8(3):701-708.
67. Daugimont L., Vandermeulen G., Defresne F., Bouzin C., Mir L.M., Bouquet C., et al. Antitumoral and antimetastatic effect of antiangiogenic plasmids in B16 melanoma: higher efficiency of the recombinant disintegrin domain of ADAM 15. Eur J Pharm Biopharm 2011, 78(3):314-319.
68. Lladser A., Ljungberg K., Tufvesson H., Tazzari M., Roos A.K., Quest A.F., et al. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 2010, 59(1):81-92.
69. Galaup A., Cazes A., Le Jan S., Philippe J., Connault E., Le Coz E., et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006, 103(49):18721-18726.
70. He X., Li W., Wang Y., Hou L., Zhu L. Inhibition of colon tumor growth by IL-15 immunogene therapy. Mol Med Rep 2012, 5(1):96-102.
71. Chuang T.F., Lee S.C., Liao K.W., Hsiao Y.W., Lo C.H., Chiang B.L., et al. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer 2009, 125(3):698-707.
72. Hanari N., Matsubara H., Hoshino I., Akutsu Y., Nishimori T., Murakami K., et al. Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21. Anticancer Res 2007, 27(4B):2305-2310.
73. Kaiga T., Sato M., Kaneda H., Iwakura Y., Takayama T., Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007, 178(12):7571-7580.
74. Tsurushima H., Yuan X., Dillehay L.E., Leong K.W. Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors. Cancer Gene Ther 2007, 14(8):706-716.
75. Matsubara H., Mizutani Y., Hongo F., Nakanishi H., Kimura Y., Ushijima S., et al. Gene therapy with TRAIL against renal cell carcinoma. Mol Cancer Ther 2006, 5(9):2165-2171.
76. Ugen K.E., Kutzler M.A., Marrero B., Westover J., Coppola D., Weiner D.B., et al. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 2006, 13(10):969-974.
77. Li S., Zhang L., Torrero M., Cannon M., Barret R. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther 2005, 12(5):942-949.
78. Tevz G., Kranjc S., Cemazar M., Kamensek U., Coer A., Krzan M., et al. Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009, 11(12):1125-1137.
79. Shimizu H., Nukui Y., Mitsuhashi N., Kimura F., Yoshidome H., Ohtsuka M., et al. Induction of antitumor response by in vivo allogeneic major histocompatibility complex gene transfer using electroporation. J Surg Res 2009, 154(1):60-67.
80. Saito T., Takayama T., Osaki T., Nagai S., Suzuki T., Sato M., et al. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity. Cancer Sci 2008, 99(10):2028-2036.
81. Peruzzi D., Mori F., Conforti A., Lazzaro D., De Rinaldis E., Ciliberto G., et al. MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res 2009, 15(12):4104-4113.
82. Zhang L., Zhao L., Zhao D., Lin G., Guo B., Li Y., et al. Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3. Cancer Gene Ther 2010, 17(3):171-179.
83. Magnon C., Opolon P., Connault E., Mir L.M., Perricaudet M., Martel-Renoir D. Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment. Gene Ther 2008, 15(21):1436-1445.
84. Ivanov M.A., Lamrihi B., Szyf M., Scherman D., Bigey P. Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy. J Gene Med 2003, 5(10):893-899.
85. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811.
86. Lares M.R., Rossi J.J., Ouellet D.L. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010, 28(11):570-579.
87. Phalon C., Rao D.D., Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med 2010, 12:e26.
88. Marques J.T., Williams B.R. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005, 23(11):1399-1405.
89. Chabot S., Pelofy S., Paganin-Gioanni A., Teissie J., Golzio M. Electrotransfer of RNAi-based oligonucleotides for oncology. Anticancer Res 2011, 31(12):4083-4089.
90. Takahashi Y., Nishikawa M., Kobayashi N., Takakura Y. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. J Control Release 2005, 105(3):332-343.
91. Golzio M., Mazzolini L., Ledoux A., Paganin A., Izard M., Hellaudais L., et al. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther 2007, 14(9):752-759.
92. Eefting D., Grimbergen J.M., de Vries M.R., van Weel V., Kaijzel E.L., Que I., et al. Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. Hum Gene Ther 2007, 18(9):861-869.
93. Nakai N., Kishida T., Shin-Ya M., Imanishi J., Ueda Y., Kishimoto S., et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 2007, 14(4):357-365.
94. Nakai N., Kishida T., Hartmann G., Katoh N., Imanishi J., Kishimoto S., et al. Mitf silencing cooperates with IL-12 gene transfer to inhibit melanoma in mice. Int Immunopharmacol 2010, 10(4):540-545.
95. Dharmapuri S., Aurisicchio L., Biondo A., Welsh N., Ciliberto G., La Monica N. Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model. Hum Gene Ther 2009, 20(6):589-597.
96. Rejiba S., Wack S., Aprahamian M., Hajri A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007, 98(7):1128-1136.
97. Xiao H., Wu Z., Shen H., Luo A.L., Yang Y.F., Li X.B., et al. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin Pharmacol Toxicol 2008, 103(4):342-348.
98. Wu Z., Li X., Zeng Y., Zhuang X., Shen H., Zhu H., et al. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol 2011, 108(3):177-184.
99. Takei Y., Nemoto T., Mu P., Fujishima T., Ishimoto T., Hayakawa Y., et al. In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 2008, 7(1):211-221.
100. Shibata M.A., Morimoto J., Shibata E., Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 2008, 15(12):776-786.
101. Vader P., van der Meel R., Symons M.H., Fens M.H., Pieters E., Wilschut K.J., et al. Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. Angiogenesis 2011, 14(4):457-466.
102. Clape C., Fritz V., Henriquet C., Apparailly F., Fernandez P.L., Iborra F., et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 2009, 4(10):e7542.
103. Wallace M., Evans B., Woods S., Mogg R., Zhang L., Finnefrock A.C., et al. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther 2009, 17(5):922-928.
104. Ball C., Thomson K.R., Kavnoudias H. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth Analg 2010, 110(5):1305-1309.
105. Rubinsky B., Onik G., Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol Cancer Res Treat 2007, 6(1):37-48.
106. Esser A.T., Smith K.C., Gowrishankar T.R., Weaver J.C. Towards solid tumor treatment by irreversible electroporation: intrinsic redistribution of fields and currents in tissue. Technol Cancer Res Treat 2007, 6(4):261-274.
107. Al-Sakere B., Andre F., Bernat C., Connault E., Opolon P., Davalos R.V., et al. Tumor ablation with irreversible electroporation. PLoS ONE 2007, 2(11):e1135.
108. Bodles-Brakhop A.M., Heller R., Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009, 17(4):585-592.
109. Lucas M.L., Heller L., Coppola D., Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002, 5(6):668-675.
110. Lucas M.L., Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 2003, 22(12):755-763.
111. Heller L., Merkler K., Westover J., Cruz Y., Coppola D., Benson K., et al. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin Cancer Res 2006, 12(10):3177-3183.
112. Daud A.I., DeConti R.C., Andrews S., Urbas P., Riker A.I., Sondak V.K., et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008, 26(36):5896-5903.
113. Richards J.M., Gonzalez R., Schwarzenberger P., Whitman E., Stardal K., Westhoff C., et al. Phase I trial of IL-2 plasmid DNA with electroporation in metastatic melanoma. J Clin Oncol 2007, 25(18S):8578.
114. Chiarella P., Fazio V.M., Signori E. Application of electroporation in DNA vaccination protocols. Curr Gene Ther 2010, 10(4):281-286.
115. Chiarella P., Fazio V.M., Signori E. DNA vaccination by electrogene transfer. Non-viral gene therapy 2011, InTech, Rijeka, Croatia. X. Yuan (Ed.).
116. Ginsberg A.A., Shen X., Hutnick N.A., Weiner D.B. Improvement of DNA vaccines by electroporation gene vaccines. Gene vaccines 2012, 145-162. Springer, New York. J. Thalhamer, R. Weiss, S. Scheiblhofer (Eds.).
117. Weber L.W., Bowne W.B., Wolchok J.D., Srinivasan R., Qin J., Moroi Y., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998, 102(6):1258-1264.
118. Bowne W.B., Srinivasan R., Wolchok J.D., Hawkins W.G., Blachere N.E., Dyall R., et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999, 190(11):1717-1722.
119. + T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res 2002, 62(19):5489-5494.
120. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003, 9(4):1284-1290.
121. Bergman P.J., Camps-Palau M.A., McKnight J.A., Leibman N.F., Craft D.M., Leung C., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 2006, 24(21):4582-4585.
122. Liao J.C., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006, 6:8.
123. Wolchok J.D., Yuan J., Houghton A.N., Gallardo H.F., Rasalan T.S., Wang J., et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007, 15(11):2044-2050.
124. Durrant L.G., Pudney V.A., Spendlove I. Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Rev Vaccines 2011, 10(7):1093-1106.
125. Low L., Mander A., McCann K., Dearnaley D., Tjelle T., Mathiesen I., et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009, 20(11):1269-1278.
126. Vittes G.E., Harden E.L., Ottensmeier C.H., Rice J., Stevenson F.K. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. Eur J Immunol 2011, 41(8):2447-2456.
127. Chaise C., Buchan S.L., Rice J., Marquet J., Rouard H., Kuentz M., et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008, 112(7):2956-2964.